Table 2.
Small molecular metabolite targets and their agents in rheumatoid arthritis.
| Targets | Agents | Phases | References |
|---|---|---|---|
| PGs targets | |||
| PGD2 | MK0524 | Animal study | (142) |
| PGE2 | ER-819762 | Animal study | (143) |
| CR6086 | Animal study | (144) | |
| PGI2 | Iloprost | Phase 2 | (145) |
| PGJ2 | 15d-PGJ2 | Animal study | (146) |
| PGF2α | AL‐8810 | Animal study | (147) |
| TXA2 | SQ29548 | Animal study | (148) |
| LTs targets | |||
| LTB4R | BIIL 284 | Phase 1 | (149) |
| CysLT1R | Montelukast | Animal study | (150) |
| LXs targets | |||
| ALX | BML-111 | Animal study | (151) |
| PAF targets | |||
| PAFR | WB2086 | Animal study | (152) |
| ROS targets | |||
| ROS | Cinnamaldehyde | Cell culture | (153) |
| Eugenol | Cell culture | (153) | |
| NO targets | |||
| iNOS | GW274150 | Phase 2 | (154) |
| L-NAME | Animal study | (155) | |
| Other small molecular targets | |||
| CB2 | HU-308 | Animal study | (156) |
| JWH-015 | Animal study | (157) | |
| FFAH | URB597 | Animal study | (158) |
| NAGly | Animal study | (159) | |
PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGI2, prostaglandin I2; PGJ2, prostaglandin J2; TXA2, thromboxane A2; LTB4R, leukotriene B4 receptor; CysLT1R, cysteine leukotrienes 1 receptor; ALX, lipoxin A4 receptor; PAF, platelet-activating factor; PAFR, platelet-activating factor receptor; iNOS, inducible nitric oxide synthase; CB2, cannabinoid receptor 2; FFAH, specific fatty acid amide hydrolase; NAGly, N-arachidonic glycine.